. J Biol Chem 273:3273032738. 4. Bennett RG, Hamel FG, Duckworth WC An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 52:23152320. five. Shen Y, Joachimiak A, Rosner MR, Tang WJ Structures of human insulin-degrading enzyme reveal a new substrate BTZ-043 biological activity recognition mechanism. Nature 443:870874. six. Jackson K, Barisone GA, Diaz E, Jin LW, Decarli C, et al. Amylin deposition in the brain: A second amyloid in Alzheimer disease Ann Neurol 74: 517526. 7. Banks WA, Kastin AJ Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19:883889. 8. Olsson M, Herrington MK, Reidelberger RD, Permert J, Arnelo U Comparison on the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on meals intake and meal pattern in the rat. Peptides 28:14161423. 9. Lutz TA Effects of amylin on eating and adiposity. Handb Exp Pharmacol:231250. 6 Amylin and Amyloid-Beta Peptides ten. Roth JD, Roth JD, Erickson MR, Chen S, Parkes DG Amylin along with the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future possibilities. Curr Opin Endocrinol Diabetes Obes 20:813. 11. Westfall TC, Curfman-Falvey M Amylin-induced relaxation from the perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors. J Cardiovasc Ergocalciferol Pharmacol 26:932936. 12. Edvinsson L, Goadsby PJ, Uddman R Amylin localization, effects on cerebral arteries and on nearby cerebral blood flow within the cat. Scientific World Journal 1:168180. 13. Trevaskis JL, Turek VF, Wittmer C, Griffin PS, Wilson JK, et al. Enhanced amylin-mediated physique weight loss in estradiol-deficient diet-induced obese rats. Endocrinology 151:56575668. 14. Deane R, Wu Z, Sagare A, 22948146 Davis J, Du Yan S, et al LRP/amyloid betapeptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333344. 15. Sagare AP, Bell RD, Zlokovic BV Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med 2. 16. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, et al. No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int 55:820825. 17. Hardy J, Selkoe DJ The amyloid hypothesis of Alzheimer’s illness: progress and challenges around the road to therapeutics. Science 297:353356. 18. Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability with the amyloid beta monoclonal antibody solanezumab in Japanese and white sufferers with mild to moderate alzheimer illness. Clin Neuropharmacol 35:2529. 19. Tanzi RE, Bertram L New frontiers in Alzheimer’s disease genetics. Neuron 32:181184. 20. Bell RD, Zlokovic BV Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118:103113. 21. Sun X, Steffens DC, Au R, Folstein M, Summergrad P, et al. Amyloidassociated depression: a prodromal depression of Alzheimer illness Arch Gen Psychiatry 65:542550. 22. Scott TM, Peter I, Tucker KL, Arsenault L, Bergethon P, et al. The Nutrition, Aging, and Memory in Elders study: style and procedures to get a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psy.. J Biol Chem 273:3273032738. four. Bennett RG, Hamel FG, Duckworth WC An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 52:23152320. 5. Shen Y, Joachimiak A, Rosner MR, Tang WJ Structures of human insulin-degrading enzyme reveal a brand new substrate recognition mechanism. Nature 443:870874. 6. Jackson K, Barisone GA, Diaz E, Jin LW, Decarli C, et al. Amylin deposition in the brain: A second amyloid in Alzheimer illness Ann Neurol 74: 517526. 7. Banks WA, Kastin AJ Differential permeability with the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19:883889. eight. Olsson M, Herrington MK, Reidelberger RD, Permert J, Arnelo U Comparison from the effects of chronic central administration and chronic peripheral administration of islet amyloid polypeptide on food intake and meal pattern in the rat. Peptides 28:14161423. 9. Lutz TA Effects of amylin on eating and adiposity. Handb Exp Pharmacol:231250. 6 Amylin and Amyloid-Beta Peptides ten. Roth JD, Roth JD, Erickson MR, Chen S, Parkes DG Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Curr Opin Endocrinol Diabetes Obes 20:813. 11. Westfall TC, Curfman-Falvey M Amylin-induced relaxation of your perfused mesenteric arterial bed: meditation by calcitonin gene-related peptide receptors. J Cardiovasc Pharmacol 26:932936. 12. Edvinsson L, Goadsby PJ, Uddman R Amylin localization, effects on cerebral arteries and on nearby cerebral blood flow in the cat. Scientific World Journal 1:168180. 13. Trevaskis JL, Turek VF, Wittmer C, Griffin PS, Wilson JK, et al. Enhanced amylin-mediated physique fat loss in estradiol-deficient diet-induced obese rats. Endocrinology 151:56575668. 14. Deane R, Wu Z, Sagare A, 22948146 Davis J, Du Yan S, et al LRP/amyloid betapeptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333344. 15. Sagare AP, Bell RD, Zlokovic BV Neurovascular dysfunction and faulty amyloid beta-peptide clearance in Alzheimer disease. Cold Spring Harb Perspect Med two. 16. Le Bastard N, Aerts L, Leurs J, Blomme W, De Deyn PP, et al. No correlation among time-linked plasma and CSF Abeta levels. Neurochem Int 55:820825. 17. Hardy J, Selkoe DJ The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353356. 18. Uenaka K, Nakano M, Willis BA, Friedrich S, Ferguson-Sells L, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer illness. Clin Neuropharmacol 35:2529. 19. Tanzi RE, Bertram L New frontiers in Alzheimer’s disease genetics. Neuron 32:181184. 20. Bell RD, Zlokovic BV Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118:103113. 21. Sun X, Steffens DC, Au R, Folstein M, Summergrad P, et al. Amyloidassociated depression: a prodromal depression of Alzheimer illness Arch Gen Psychiatry 65:542550. 22. Scott TM, Peter I, Tucker KL, Arsenault L, Bergethon P, et al. The Nutrition, Aging, and Memory in Elders study: design and style and strategies to get a study of micronutrients and cognitive function within a homebound elderly population. Int J Geriatr Psy.
